Business Context and Reporting Period
This Form 8-K, filed on March 6, 2015, reports on events occurring on March 5, 2015, involving Targacept, Inc. (the "Company"). The filing details the entry into a definitive merger agreement with Catalyst Biosciences, Inc. ("Catalyst"). Upon consummation, Catalyst will become a wholly-owned subsidiary of Targacept, and the combined entity will operate under the name Catalyst Biosciences, Inc.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins for the reporting period. Key financial terms of the proposed transaction include:
- Exchange Ratio: Catalyst shareholders will receive approximately 0.40 to 0.49 shares of Targacept common stock for each share of Catalyst common stock.
- Ownership Structure: Post-merger, Catalyst stockholders are expected to own approximately 65% of the combined company. Targacept stockholders are expected to own approximately 49% on a pro-forma basis if convertible notes are fully converted.
- Pre-Closing Dividend: Targacept intends to pay a dividend of approximately $37 million in redeemable convertible notes and approximately $20 million in cash to its stockholders prior to closing.
- Note Terms: The convertible notes have a conversion price of $1.31 per share (130% of the negotiated per-share asset value) and are convertible or redeemable within two years after closing.
- Termination Fees: Targacept may be required to pay Catalyst up to $3.22 million plus up to $1.25 million in expense reimbursements. Catalyst may be required to pay Targacept $2.275 million under specified termination circumstances.
Material Changes and Corporate Actions
The primary material change is the execution of the Merger Agreement, which fundamentally alters the corporate structure and ownership of both entities. Additional material actions include:
- Board Composition: The post-merger Board of Directors will consist of four current Catalyst directors (including Chairman Harold E. Selick) and three current Targacept directors.
- Bylaw Amendment: Effective March 5, 2015, Targacept amended its bylaws to require that certain stockholder actions regarding internal affairs be brought exclusively in the Court of Chancery of the State of Delaware or federal district courts in Delaware.
- Asset Disposition: Targacept's NNR assets will be placed in a liquidating trust if not sold prior to closing, with proceeds distributed to Targacept stockholders entitled to the Pre-Closing Dividend.
- Stock Split: Targacept plans to effect a reverse stock split to satisfy NASDAQ Global Select Market listing requirements.
Guidance, Risks, and Contingencies
The filing outlines several conditions and risks associated with the transaction:
- Closing Conditions: The merger is subject to stockholder approval from both Targacept and Catalyst, as well as other conditions set forth in the Merger Agreement.
- Support Agreements: Significant voting agreements and a 120-day lock-up agreement have been entered into by officers, directors, and stockholders holding approximately 43% of Targacept and 84% of Catalyst to support the merger.
- Regulatory Filings: Targacept intends to file a registration statement on Form S-4 containing a prospectus and joint proxy statement for stockholder review.
- Disclaimer: The filing explicitly states that the Merger Agreement and this summary should not be relied upon as factual disclosure about the companies' actual state of facts or conditions, as representations and warranties are subject to negotiation and confidential schedules.
Investor Verification Checklist
- Verify the final exchange ratio and pro-forma ownership percentages once the Form S-4 is filed.
- Confirm the status of the Pre-Closing Dividend and the specific terms of the $37 million convertible notes.
- Review the upcoming proxy statement for details on the reverse stock split ratio and the exact composition of the new Board of Directors.
- Monitor the progress of stockholder approvals required for the merger to close.
- Assess the potential impact of the termination fees ($3.22 million or $2.275 million) on the combined entity's liquidity if the deal fails.